[2021] Global Weight Loss and Obesity Management Market Size, Emerging Growth, Growing At a CAGR of 7.1%, | Coherent Market Insights

SEATTLE, May 04, 2021, (PHARMIWEB) — 

Obesity refers to body fat and body mass index above 25 (overweight) and 30 (obese), respectively. It is one of the most prevalent disease conditions across the world. It affects individuals in developed, emerging, and undeveloped regions. The weight loss and obesity management services involve the use of certain products such as dietary supplements, medications, surgical interventions, and fitness equipment. According to the World Health Organization, when the Body-Mass-Index is greater than or equal to 25, the person is categorized as overweight; and BMI index above 30 is classified as obese.

The global weight loss and obesity management market is projected to rise due to the rising prevalence of obesity.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3448

Obesity is described as having too much body fat and a high BMI (body mass index). Obesity has a BMI index of more than 30. Obesity is one of the most common diseases in the world, affecting people in developed, emerging, and developing countries alike.

Over the forecast period, the global weight loss and obesity management market is expected to rise due to the rising prevalence of obesity. As per statistics released by the World Health Organization (WHO) in 2018, the number of obese people has tripled since 1975, with almost 41 million children worldwide now obese.

During the forecast period, the global weight loss and obesity management market is projected to grow due to increased strategic alliances and research by key players to improve their product portfolio. VIVUS, Inc., a biopharmaceutical firm, announced in May 2019 that phase IV protection and effectiveness testing for Qsymia for weight control in obese patients had begun.

In the global weight loss and obesity management market, key players are focusing on tactics such as acquisitions to broaden their product range and regional reach. NovoFit, a major fitness equipment provider, announced a strategic alliance with Amer Sports’ leading fitness company, Precor, for product distribution in Australia in June 2019. NovaFit and Amer Sports’ market positioning in Australia is expected to improve as a result of the collaboration.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3448

Due to rising prevalence of chronic diseases such as cancer, maker investments, and product releases, the global weight loss and obesity management market is projected to grow at a CAGR of 7.1 percent during the forecast period. Gelesis, a biotechnology firm, obtained FDA clearance for PLENITY for weight control in adults with a BMI of 25 to 40 kg/m2 in April 2019.

In the global weight loss and obesity management market, the drugs segment is projected to grow at the fastest rate over the forecast period. This can be due to an increase in product approvals as well as increased R&D operation. Novo Nordisk obtained FDA clearance for Oral semaglutide (Rybelsus) to treat type 2 diabetes in September of this year, and the medication can also be used to help type 2 diabetes patients lose weight.

Due to the rising prevalence of obesity, the adults segment holds a leading spot in the global Weight Loss and Obesity Management market. As per a survey released by the World Health Organization in 2018, almost 650 million people worldwide were obese in 2016.

Key companies contributing in the global weight loss and obesity management market are Brunswick Corporation, Amer Sports, Apollo Endosurgery (U.S.), Eisai Co., Ltd., Herbalife Ltd., Kellogg Company, NutriSystem, Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd, Medtronic, Life Time Fitness Inc., VIVUS Inc., Johnson & Johnson Services, Inc., Equinox, Inc., F. Hoffmann-La Roche Ltd, Ethicon Inc., Duke Products & Services & Fitness Center, and Cybex International.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3448

Detailed Segmentation:

By Product & Services:

• • Drugs
    • Bupropion-naltrexone (Contrave)
    • Liraglutide (Saxenda)
    • Lorcaserin (Belviq)
    • Orlistat (Xenical)
    • Phentermine-topiramate (Qsymia)
    • Others
  • Supplements
  • Equipment
    • Fitness Equipment
    • Surgical Equipment
  • Services
    • Consulting Service
    • Online Weight Loss Programs
    • Others

By Age Group:

• • Children
  • Adults
  • Geriatrics

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/weight-loss-and-obesity-management-market-2797  

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. Shah
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com